MX2017014700A - Neoantigenos compartidos. - Google Patents

Neoantigenos compartidos.

Info

Publication number
MX2017014700A
MX2017014700A MX2017014700A MX2017014700A MX2017014700A MX 2017014700 A MX2017014700 A MX 2017014700A MX 2017014700 A MX2017014700 A MX 2017014700A MX 2017014700 A MX2017014700 A MX 2017014700A MX 2017014700 A MX2017014700 A MX 2017014700A
Authority
MX
Mexico
Prior art keywords
tumor
subjects
specific
population
neoantigenic
Prior art date
Application number
MX2017014700A
Other languages
English (en)
Inventor
Bachireddy Pavan
Ashok Shukla Sachet
J Wu Catherine
Steven Rooney Michael
Sun Jing
Hacohen Nir
F Fritsch Edward
Original Assignee
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc filed Critical Broad Inst Inc
Publication of MX2017014700A publication Critical patent/MX2017014700A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
    • A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se divulga aquí en un aspecto una composición farmacéutica que comprende una pluralidad de péptidos neoantigénicos y un portador farmacéuticamente aceptable, cada péptido neoantigénico que comprende un neoepítopo específico a tumor capaz de unirse a una proteína HLA en un sujeto, cada neoepítopo específico a tumor comprende una mutación específica a tumor presente en un tumor, en el que (a) la composición comprende péptidos neoantigénicos que comprenden mutaciones específicas a tumor presente en por lo menos 1% de lo sujetos en una población de sujetos que sufren de cáncer; (b) la composición comprende péptidos neoantigénicos que comprenden neoepítopos específicos a tumores que se unen a proteínas HLA presentes en por lo menos 5% de lo sujetos en la población; y (c) la composición comprende por lo menos un péptido neoantigénico capaz de provocar una respuesta inmunitaria contra un tumor presente en por lo menos 5% de los sujetos en la población de sujetos que sufren de cáncer.
MX2017014700A 2015-05-20 2016-05-20 Neoantigenos compartidos. MX2017014700A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562179877P 2015-05-20 2015-05-20
US201662389377P 2016-02-23 2016-02-23
PCT/US2016/033452 WO2016187508A2 (en) 2015-05-20 2016-05-20 Shared neoantigens

Publications (1)

Publication Number Publication Date
MX2017014700A true MX2017014700A (es) 2018-08-15

Family

ID=56203902

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014700A MX2017014700A (es) 2015-05-20 2016-05-20 Neoantigenos compartidos.
MX2023005122A MX2023005122A (es) 2015-05-20 2017-11-16 Neoantigenos compartidos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023005122A MX2023005122A (es) 2015-05-20 2017-11-16 Neoantigenos compartidos.

Country Status (21)

Country Link
US (2) US10835585B2 (es)
EP (1) EP3297660A2 (es)
JP (3) JP6913032B2 (es)
KR (1) KR20180010229A (es)
CN (2) CN116196401A (es)
AU (2) AU2016264623B2 (es)
BR (1) BR112017024797A2 (es)
CA (1) CA2986235A1 (es)
CL (2) CL2017002945A1 (es)
CO (1) CO2017012835A2 (es)
CR (3) CR20200476A (es)
EC (1) ECSP17084137A (es)
HK (2) HK1251148A1 (es)
IL (3) IL302102A (es)
MX (2) MX2017014700A (es)
MY (1) MY190974A (es)
PE (1) PE20180670A1 (es)
PH (1) PH12017502321A1 (es)
RU (2) RU2020132040A (es)
TW (2) TWI806815B (es)
WO (1) WO2016187508A2 (es)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738026C (en) 2008-09-22 2017-01-24 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
DK3106463T6 (da) 2008-10-22 2020-02-24 Array Biopharma Inc Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
HUE035337T2 (en) 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
DK3699181T3 (da) 2014-11-16 2023-03-20 Array Biopharma Inc Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
RU2020132040A (ru) 2015-05-20 2020-10-12 Те Брод Инститьют Инк. Общие неоантигены
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
WO2017124147A1 (en) * 2016-01-19 2017-07-27 The University Of Western Australia Novel biomolecule conjugates and uses therefor
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
US11154597B2 (en) 2016-03-24 2021-10-26 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
PE20181888A1 (es) 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
CA3056212A1 (en) * 2016-04-07 2017-10-12 Bostongene Corporation Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
WO2017190218A1 (en) * 2016-05-06 2017-11-09 University Health Network Liquid-biopsy signatures for prostate cancer
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018094569A1 (zh) * 2016-11-22 2018-05-31 深圳华大基因研究院 多肽及其应用
CN109952308B (zh) * 2016-11-29 2022-09-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
EP3548897A4 (en) * 2016-12-01 2020-08-12 Nantomics, LLC PRESENTATION AND TREATMENT OF TUMOR ANTIGENICITY
EP4119663A1 (en) 2016-12-09 2023-01-18 The Broad Institute, Inc. Crispr effector system based diagnostics
US11634486B2 (en) 2016-12-23 2023-04-25 Bluefin Biomedicine, Inc. Anti-SEZ6L2 antibodies and antibody drug conjugates
EP3568157A4 (en) * 2017-01-13 2021-01-06 National Research Council of Canada METHOD FOR OPTIMIZING THE PEPTIDE IMMUNO-EPITOP BY GLYCOSYLATION, OPTIMIZED PEPTIDE THEREOF AND ITS USE FOR CONJUGATE VACCINES
NZ755835A (en) 2017-01-17 2023-12-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018136664A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN117224710A (zh) 2017-02-01 2023-12-15 莫得纳特斯公司 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物
US11771749B2 (en) 2017-02-03 2023-10-03 The Medical College Of Wisconsin, Inc. KRAS peptide vaccine compositions and method of use
CN106868133A (zh) * 2017-02-24 2017-06-20 北京致成生物医学科技有限公司 一种监测肿瘤发生发展的产品及其应用
BR112019019087A2 (pt) 2017-03-15 2020-05-12 The Broad Institute, Inc. Diagnóstico baseado em sistema efetor de crispr para detecção de vírus
US11174515B2 (en) 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN108659114B (zh) * 2017-04-01 2022-10-21 中国科学院广州生物医药与健康研究院 识别pasd1抗原短肽的tcr
CA3061240C (en) 2017-04-24 2024-01-16 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
WO2018209015A1 (en) * 2017-05-10 2018-11-15 University Of Connecticut Dendritic cells as a novel delivery system for immunotherapy
CA3063905A1 (en) * 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
EP3641803A2 (en) 2017-06-21 2020-04-29 Transgene Personalized vaccine
ES2950653T3 (es) * 2017-06-22 2023-10-11 Neogap Therapeutics Ab Método de expansión de linfocitos T y usos
NL2019156B1 (en) * 2017-06-30 2019-01-10 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Treatment of haematological malignancies
WO2019004831A1 (en) * 2017-06-30 2019-01-03 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) TREATMENT OF HEMATOLOGICAL MALIGNANCIES
CN107325171A (zh) * 2017-07-06 2017-11-07 江苏迈健生物科技发展股份有限公司 抗原肽t790m‑7及其在制备治疗非小细胞肺癌的药物中的应用
CN107188955A (zh) * 2017-07-06 2017-09-22 江苏迈健生物科技发展股份有限公司 抗原肽t790m‑3及其在制备治疗非小细胞肺癌的药物中的应用
SG11202000250PA (en) * 2017-07-12 2020-02-27 Nouscom Ag A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
WO2019031939A2 (ko) * 2017-08-10 2019-02-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
CN111315390A (zh) * 2017-09-05 2020-06-19 磨石肿瘤生物技术公司 用于t细胞疗法的新抗原鉴别
JP7320840B2 (ja) 2017-09-11 2023-08-04 国立大学法人北海道大学 癌治療薬
AU2018342246A1 (en) * 2017-09-29 2020-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing mutated p53
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
AU2019213047A1 (en) 2018-01-29 2020-07-16 Massachusetts Institute Of Technology CRISPR effector system based diagnostics
US20210038703A1 (en) * 2018-02-15 2021-02-11 National University Corporation Asahikawa Medical University Cancer Antigen Peptide
US20210238690A1 (en) * 2018-04-26 2021-08-05 Intellexon Gmbh Hla-j and medical/diagnostic uses thereof
CN108588201B (zh) * 2018-05-11 2019-08-09 浙江省人民医院 一种结直肠癌西妥昔单抗耐药性痕量dna突变检测的方法及装置
EP4252759A3 (en) * 2018-05-11 2023-11-08 Memorial Sloan Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
CN108588050B (zh) * 2018-05-14 2021-06-25 北京艾克伦医疗科技有限公司 Dna聚合酶以及核酸检测方法和试剂盒
CA3100974A1 (en) * 2018-05-25 2020-11-28 The Wistar Institute Tumor-specific neoantigens and methods of using the same
CN108728529B (zh) * 2018-06-06 2020-08-04 青岛泱深生物医药有限公司 Znf770基因在制备诊治子痫前期的产品中的应用
CN110577953B (zh) * 2018-06-11 2024-02-20 深圳华大生命科学研究院 基因突变体及其应用
CN109142729B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-hmgb3自身抗体及其应用
WO2019243272A1 (en) * 2018-06-18 2019-12-26 College De France Ligand controling interaction between gags with their effector molecules and use thereof
JP2021527655A (ja) * 2018-06-19 2021-10-14 ビオンテック ユーエス インコーポレイテッド ネオ抗原およびそれらの使用
TW202015719A (zh) * 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
GB201810358D0 (en) * 2018-06-25 2018-08-08 Univ College Cardiff Consultants Ltd Cancer-specific t-cell receptors
EP3827266A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
CA3106573A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
US20220349010A1 (en) 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
US20210213116A1 (en) 2018-07-26 2021-07-15 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
CA3106574A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
US20210162032A1 (en) 2018-07-26 2021-06-03 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
CN113728102A (zh) * 2018-08-28 2021-11-30 罗氏创新中心哥本哈根有限公司 使用剪接调节化合物进行新抗原工程化
EP3846844A1 (en) * 2018-09-05 2021-07-14 Vaximm AG Neoantigen targeting dna vaccine for combination therapy
CN109022585A (zh) * 2018-09-10 2018-12-18 路君 Pbld基因在制备肾透明细胞癌诊断和预测预后药物中的应用
CA3113207A1 (en) * 2018-09-20 2020-03-26 Daiichi Sankyo Company, Limited Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate
CN109207431B (zh) * 2018-10-12 2021-10-15 武汉大学 一种抑制人癌基因STAT3的α亚型表达的方法
CN109486935A (zh) * 2018-10-18 2019-03-19 中国医学科学院北京协和医院 作为骨质疏松症诊治靶标的aknad1基因
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用
CN111116754A (zh) * 2018-10-30 2020-05-08 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性tcr及其应用
WO2020092705A1 (en) * 2018-10-31 2020-05-07 University Of Virginia Patent Foundation Self-assembling peptides and hydrogels
CA3122378A1 (en) * 2018-11-01 2020-05-07 The Broad Institute, Inc. Identification of pde3 modulator responsive cancers
CN109504771A (zh) * 2018-11-19 2019-03-22 北京大学深圳医院（北京大学深圳临床医学院） Adcy2作为乳腺癌的分子标记物的应用
CN109438570B (zh) * 2018-11-28 2021-07-20 生命谷（海南）生物科技股份有限公司 肿瘤相关基因fgfr3突变短肽及其应用
CN109371026A (zh) * 2018-12-11 2019-02-22 宁夏医科大学总医院 一种环状RNA hsa_circACACB_035及其特异性扩增引物和应用
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
CN111363816B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于pax3和zic4基因的肺癌诊断试剂及试剂盒
CN109576362B (zh) * 2018-12-28 2020-09-04 青岛泱深生物医药有限公司 阿尔茨海默诊治用标志物fam170a
TW202043256A (zh) * 2019-01-10 2020-12-01 美商健生生物科技公司 ***新抗原及其用途
CN109504778B (zh) * 2019-01-11 2021-11-09 复旦大学附属中山医院 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型
CN113905753A (zh) * 2019-01-15 2022-01-07 康奈尔大学 重组粘蛋白和组合物以及其使用方法
CN112687352B (zh) * 2019-01-29 2022-07-15 杭州纽安津生物科技有限公司 针对靶向药物依鲁替尼的多肽疫苗组合及其设计方法
WO2020168047A1 (en) * 2019-02-13 2020-08-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination of t-cell therapy and targeted therapy for treating therapy-resistant melanoma with mutations in the braf gene
JP2022521738A (ja) 2019-02-20 2022-04-12 ルビウス セラピューティクス， インコーポレイテッド 負荷可能な抗原提示ポリペプチドを含む操作された赤血球系細胞および使用方法
CN109735624A (zh) * 2019-03-14 2019-05-10 台州市立医院 基因标志物在甲状腺癌诊断中的应用
EP3941932A1 (en) * 2019-03-21 2022-01-26 Institute for Research in Biomedicine Peptide inhibitors targeting the cxcl12/hmgb1 interaction and uses thereof
IL266728B (en) * 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
TW202110870A (zh) 2019-05-30 2021-03-16 美商葛利史東腫瘤科技公司 經修飾之腺病毒
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
US11306122B2 (en) * 2019-06-14 2022-04-19 The United States Government As Represented By The Department Of Veterans Affairs Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor
CN114245745A (zh) * 2019-06-20 2022-03-25 纪念斯隆-凯特琳癌症中心 靶向pik3ca突变的t细胞受体及其用途
CN110358827A (zh) * 2019-07-09 2019-10-22 中国人民解放军第四军医大学 Vmp1基因在病理诊断胶质母细胞瘤中的应用及其试剂盒的制备
CN110358831B (zh) * 2019-07-11 2021-12-24 江苏医药职业学院 检测跨膜蛋白41a表达水平的试剂的应用和试剂盒
EP3997131A4 (en) * 2019-07-12 2023-08-02 The Regents of the University of California CHEMICALLY DRIVEN MONOCLONAL ANTIBODY TARGETING
EP3999547A4 (en) * 2019-07-16 2023-07-12 Washington University ANTI-GRP78 ANTIBODIES AND METHODS OF USE THEREOF
EP4003390A4 (en) * 2019-07-30 2024-03-13 Breakbio Corp METHOD FOR TREATING SOLID TUMORS
US11752197B2 (en) 2019-08-12 2023-09-12 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
CN112402612B (zh) * 2019-08-21 2023-05-26 苏州蓝马医疗技术有限公司 一种提高肿瘤新抗原疫苗免疫治疗疗效的方法
EP4055059A4 (en) * 2019-11-06 2024-01-10 Ohio State Innovation Foundation TARGETING CIRCULAR PCMTD1 IN LEUKEMIA WITH P53 MUTATIONS AND/OR BCR/ABL FUSIONS
KR20220098379A (ko) * 2019-11-15 2022-07-12 그릿스톤 바이오, 인코포레이티드 공유 네오항원을 표적으로 하는 항원-결합 단백질
CA3165862A1 (en) 2019-12-23 2021-07-01 The Regents Of The University Of California Stabilization of mhc complexes
CN113117081A (zh) * 2019-12-30 2021-07-16 上海海洋大学 ZC3H12b基因或蛋白的用途及一种肝脏疾病动物模型的建立方法
EP4085130A4 (en) * 2019-12-31 2024-04-10 Elixirgen Therapeutics Inc TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES
CN111116728B (zh) * 2020-01-13 2021-04-27 郑州大学 肿瘤特异性抗原ctl表位肽及其应用
US20230080534A1 (en) * 2020-01-21 2023-03-16 Shanghai Biotroy Biotechnique Co., Ltd. Semg2 antibody and use thereof
WO2021168355A1 (en) * 2020-02-20 2021-08-26 Gritstone Bio, Inc. Antigen-binding proteins targeting kklc-1 shared antigen
CN111303268B (zh) * 2020-03-10 2021-08-27 江苏兰恩生物治疗技术研究院有限公司 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗
CN114315964B (zh) * 2020-03-18 2023-06-13 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
CN113817740A (zh) * 2020-06-19 2021-12-21 中国科学院化学研究所 一种核酸适配体识别并结合ptprf及其相关功能的应用研究
CN111718405B (zh) * 2020-06-30 2022-09-13 青岛海兰深生物科技有限公司 一种检测抗胰腺癌天然抗体的组合物、试剂盒和方法
WO2022000399A1 (en) * 2020-07-02 2022-01-06 The Johns Hopkins University Methylated markers for accurate detection of primary central nervous system and systemic diffuse large b cell lymphoma
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
KR20230086765A (ko) 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
JP2023551204A (ja) * 2020-11-20 2023-12-07 シンク・セラピューティクス・インコーポレイテッド 最適化ペプチドワクチンの組成物および方法
WO2022140759A2 (en) * 2020-12-23 2022-06-30 Janssen Biotech, Inc. Neoantigen peptide mimics
CN112666358A (zh) * 2021-01-14 2021-04-16 深圳裕康医学检验实验室 一种使用外周血检测抗原免疫原性的方法
CN113150140B (zh) * 2021-01-25 2022-11-04 山西农业大学 一种sox6二价纳米抗体及其应用
WO2022179568A1 (en) * 2021-02-25 2022-09-01 Westlake Therapeutics (Hangzhou) Co., Limited Neoantigenic peptide and its use for treating braf gene mutation related diseases
AU2022240549A1 (en) * 2021-03-16 2023-10-05 Shanghai Biotroy Biotechnique Co., Ltd Semenogelin neutralizing antibody and epitope and application thereof
CN113667002B (zh) * 2021-03-24 2023-03-28 深圳市新靶向生物科技有限公司 一种与肺癌驱动基因突变相关的抗原肽及其应用
CN113321724B (zh) * 2021-03-24 2022-02-01 深圳市新靶向生物科技有限公司 一种与食道癌驱动基因突变相关的抗原肽及其应用
CN114163512A (zh) * 2021-03-24 2022-03-11 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
IL282814A (en) * 2021-04-29 2022-11-01 Yeda Res & Dev T-cell receptors against recurrent ras-derived neoantigens
CA3214450A1 (en) 2021-04-30 2022-11-03 Tigen Pharma Sa Single vessel expansion of lymphocytes
CN113527464A (zh) * 2021-07-19 2021-10-22 新景智源生物科技(苏州)有限公司 识别mboat2的tcr
CN113721030B (zh) * 2021-08-30 2024-02-13 河南中医药大学 用于桥本甲状腺炎不同证候特征性自身抗体检测的生物标志物及其应用
CN114085281A (zh) * 2021-10-15 2022-02-25 北京臻知医学科技有限责任公司 一种肿瘤抗原表位肽及其多聚体和应用
CN114085282A (zh) * 2021-10-15 2022-02-25 北京臻知医学科技有限责任公司 一种肿瘤新生抗原表位肽Pep6及其多聚体和应用
WO2023081655A1 (en) * 2021-11-02 2023-05-11 Fred Hutchinson Cancer Center T cell immunotherapy for hematologic malignancies having an sf3b1 mutation
KR20230068628A (ko) 2021-11-11 2023-05-18 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
KR20230068627A (ko) 2021-11-11 2023-05-18 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
CN114177274A (zh) * 2021-12-13 2022-03-15 中国医学科学院微循环研究所 Tdrd10蛋白及其编码基因在制备肿瘤治疗药物中的应用、及肿瘤治疗药物
WO2023114430A1 (en) * 2021-12-16 2023-06-22 The Johns Hopkins University Manabodies targeting p53 tumor antigens and methods of using
KR20230101287A (ko) 2021-12-29 2023-07-06 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101283A (ko) 2021-12-29 2023-07-06 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101285A (ko) 2021-12-29 2023-07-06 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101286A (ko) 2021-12-29 2023-07-06 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101284A (ko) 2021-12-29 2023-07-06 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
WO2023150788A2 (en) * 2022-02-07 2023-08-10 Ubiquitx Beta-catenin protein degradation
CN117586344A (zh) * 2022-08-12 2024-02-23 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
CN115651984B (zh) * 2022-10-20 2023-04-14 山东大学 一种生物标志物在评价肿瘤紫杉类化疗耐药性的应用
CN116948004B (zh) * 2023-09-13 2023-11-21 成都朗谷生物科技股份有限公司 针对ctnnb1基因h36p突变的肿瘤新抗原多肽及其应用
CN117567591B (zh) * 2024-01-11 2024-04-26 中国人民解放军总医院 一种用于研究Tmem247蛋白的新型鼠源Tmem247抗体制备方法和应用

Family Cites Families (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4226859A (en) 1979-06-07 1980-10-07 Velsicol Chemical Corporation Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
ATE66143T1 (de) 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4743249A (en) 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4816540A (en) 1987-06-12 1989-03-28 Yasuhiko Onishi Cationic graft-copolymer
US5422119A (en) 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
CA2005291C (en) 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5198223A (en) 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6277558B1 (en) 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
AU1588092A (en) 1991-02-22 1992-09-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Transmission blocking vaccine against malaria
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5756101A (en) 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5766597A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5705190A (en) 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
IL129017A0 (en) 1996-10-17 2000-02-17 Oxford Biomedica Ltd Retroviral vectors
US7255862B1 (en) 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP0973928B1 (en) 1997-03-11 2010-05-05 Regents Of The University Of Minnesota Dna-based transposon system for the introduction of nucleic acid into dna of a cell
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
EP1015619A1 (en) 1997-09-19 2000-07-05 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
AU4800999A (en) 1998-07-28 2000-02-21 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
WO2000020587A2 (en) 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
CA2348382C (en) 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
US6537540B1 (en) 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
AU5898400A (en) 1999-06-29 2001-01-31 Epimmune, Inc. Hla binding peptides and their uses
US6955808B2 (en) 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
CA2397998A1 (en) 2000-01-28 2001-08-02 Statens Serum Institut Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
JP2004500095A (ja) 2000-02-24 2004-01-08 エクサイト　セラピーズ，　インコーポレイテッド 細胞の同時の刺激および濃縮
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001068820A1 (en) 2000-03-14 2001-09-20 Anton Mayr Altered strain of the modified vaccinia virus ankara (mva)
US6686184B1 (en) 2000-05-25 2004-02-03 President And Fellows Of Harvard College Patterning of surfaces utilizing microfluidic stamps including three-dimensionally arrayed channel networks
GB0024550D0 (es) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
NZ524661A (en) 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US6923973B1 (en) 2001-02-22 2005-08-02 Board Of Regents, The University Of Texas System Peptide and DNA immunization against Coccidioides immitis infections
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
EP1839672A3 (en) 2002-04-19 2007-11-21 Bavarian Nordic A/S Modified vaccinia virus Ankara for the vaccination of neonates
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
CA2488382A1 (en) 2002-06-05 2003-12-18 Case Western Reserve University Methods and compositions for detecting cancers
JP2005529187A (ja) 2002-06-13 2005-09-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 同種抗原の特定方法、ならびに癌治療および移植へのその使用
JP2006507921A (ja) 2002-06-28 2006-03-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 流体分散のための方法および装置
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
DE60329201D1 (de) 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd Substituierte wt1-peptide
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
ATE432290T1 (de) 2002-11-09 2009-06-15 Immunocore Ltd T ZELL REZEPTOR ßDISPLAYß
CA2511625A1 (en) 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP3616781A1 (en) 2003-04-10 2020-03-04 President and Fellows of Harvard College Formation and control of fluidic species
CA2522812C (en) 2003-04-18 2012-08-21 Idm Pharma, Inc. Hla-a2 tumor associated antigen peptides and compositions
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
MXPA06000942A (es) 2003-07-24 2006-03-30 Merial Ltd Nuevas formulaciones de vacunas.
CN104069784B (zh) 2003-08-27 2017-01-11 哈佛大学 流体物种的电子控制
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US7084247B2 (en) 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases
WO2005092928A1 (en) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
NZ550810A (en) 2004-05-19 2009-05-31 Immunocore Ltd High affinity NY-ESO T cell receptor
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
US20060008468A1 (en) 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
JP5563194B2 (ja) 2004-06-29 2014-07-30 イムノコア リミテッド 改変ｔ細胞レセプターを発現する細胞
JP4772045B2 (ja) 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
CA2597928A1 (en) 2005-02-16 2006-08-24 Lentigen Corporation Lentiviral vectors and their use
EP2248578B1 (en) 2005-03-04 2012-06-06 President and Fellows of Harvard College Method for forming multiple emulsions
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2006125962A2 (en) 2005-05-25 2006-11-30 Medigene Limited T cell receptors which specifically bind to vygfvracl-hla-a24
WO2007015540A1 (ja) 2005-08-03 2007-02-08 Medical And Biological Laboratories Co., Ltd. 細胞傷害性ｔ細胞エピトープペプチド及びその用途
DK2578685T3 (da) 2005-08-23 2019-06-03 Univ Pennsylvania Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf
US20070112754A1 (en) 2005-11-15 2007-05-17 Honeywell International Inc. Method and apparatus for identifying data of interest in a database
JP2009536313A (ja) 2006-01-11 2009-10-08 レインダンス テクノロジーズ， インコーポレイテッド ナノリアクターの形成および制御において使用するマイクロ流体デバイスおよび方法
CA2640024A1 (en) 2006-01-27 2007-08-09 President And Fellows Of Harvard College Fluidic droplet coalescence
US8793895B2 (en) 2006-02-10 2014-08-05 Praxair Technology, Inc. Lyophilization system and method
WO2007101227A2 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2530168B1 (en) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Microfluidic Devices
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2390356A1 (en) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the FASLG gene
US20100035973A1 (en) 2006-07-17 2010-02-11 Nationwide Children's Hospital, Inc. Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008038002A2 (en) 2006-09-29 2008-04-03 Medigene Limited T cell therapies
US8349167B2 (en) 2006-12-14 2013-01-08 Life Technologies Corporation Methods and apparatus for detecting molecular interactions using FET arrays
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
EP2127671B1 (en) 2007-02-07 2016-09-14 Nec Corporation Therapeutic agent for cancer
WO2008109075A2 (en) 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
AU2008231072B2 (en) 2007-03-22 2013-08-01 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
CA2689536A1 (en) 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
RU2488592C2 (ru) 2007-08-08 2013-07-27 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Пептиды направленного действия на vegfr-1/nrp-1
KR20100056523A (ko) 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｇｒｆ-1 (1-29) 및 코르티코트로핀-방출 인자의 용도
EP3192521B1 (en) 2007-10-25 2020-09-16 Toray Industries, Inc. Immune response inducer
WO2009086472A2 (en) 2007-12-28 2009-07-09 John Wayne Cancer Institute Use of methylation status of mint loci and tumor-related genes as a marker for melanoma and breast cancer
CN101970051A (zh) 2007-12-31 2011-02-09 纳诺科尔治疗公司 用于治疗心力衰竭的rna干扰
US20110097312A1 (en) 2008-02-15 2011-04-28 Board Of Regents, The University Of Texas System Anti-cancer vaccines
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
JP2012505904A (ja) 2008-10-17 2012-03-08 ジェネンテック， インコーポレイテッド 治療方法
US20100137143A1 (en) 2008-10-22 2010-06-03 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes
AU2009317161B2 (en) 2008-11-24 2014-09-11 Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
PT2413956T (pt) 2009-04-02 2016-12-30 Vaxon Biotech Identificação, optimização e utilização de epitopos crípticos hla-a24 para imunoterapia
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
PE20121359A1 (es) 2009-12-10 2012-10-15 Merck Patent Gmbh Composicion farmaceutica que comprende oligopeptidos
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CN102946907A (zh) 2010-05-28 2013-02-27 牛津生物医学（英国）有限公司 慢病毒载体向脑的递送
EP2575803B1 (en) 2010-06-02 2017-07-26 Abraxis BioScience, LLC Methods of treating bladder cancer
JP2013536240A (ja) 2010-08-24 2013-09-19 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション インターロイキン−１３受容体α２ペプチド脳がんワクチン
CN106220739A (zh) 2010-12-09 2016-12-14 宾夕法尼亚大学董事会 嵌合抗原受体‑修饰的t细胞治疗癌症的用途
AU2012206487A1 (en) 2011-01-14 2013-07-18 Genefirst Limited Methods, compositions, and kits for determining the presence/absence of a variant nucleic acid sequence
EP2478915A1 (en) 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
WO2012109600A2 (en) 2011-02-11 2012-08-16 Raindance Technologies, Inc. Methods for forming mixed droplets
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US20120295960A1 (en) 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
FI3892295T3 (fi) 2011-05-24 2023-05-10 BioNTech SE Yksilöityjä rokotteita syöpää varten
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
CN103906848B (zh) 2011-08-18 2016-03-02 雀巢产品技术援助有限公司 用于检测等位变体的组合物和方法
WO2013036201A1 (en) 2011-09-06 2013-03-14 Agency For Science, Technology And Research Polypeptide vaccine
CA2848209C (en) 2011-09-15 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
WO2013040371A2 (en) 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2013086464A1 (en) 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
US20130210014A1 (en) 2012-02-10 2013-08-15 Jeff Sharman Method for determining the prognosis and therapeutic response in chronic lymphocytic leukemia (cll) patients
WO2013123031A2 (en) 2012-02-15 2013-08-22 Veridex, Llc Highly sensitive method for detecting low frequency mutations
US20150359864A1 (en) 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
MA37681B2 (fr) 2012-05-25 2020-07-29 Cellectis Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie
WO2013188831A1 (en) 2012-06-15 2013-12-19 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
JP2015533473A (ja) 2012-07-12 2015-11-26 ペルシミューン，インコーポレイテッド 個別のがんワクチン及び適応免疫細胞療法
PL2872646T3 (pl) 2012-07-12 2018-03-30 Institut National De La Santé Et De La Recherche Médicale (Inserm) Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów
CN104507537A (zh) 2012-07-13 2015-04-08 宾夕法尼亚大学董事会 用于调节car t细胞的组合物和方法
US20150191524A1 (en) 2012-07-27 2015-07-09 The Board Of Trustees Of The University Of Illinoi Engineering t cell receptors
EP2897631A4 (en) 2012-08-31 2016-10-05 Univ Virginia Patent Found TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSIS
EP2898096B1 (en) 2012-09-21 2024-02-14 The Broad Institute, Inc. Methods for labeling of rnas
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
WO2014056986A1 (en) 2012-10-11 2014-04-17 Universitat De Barcelona Method to predict the clinical evolution of a patient suffering of chronic lymphocytic leukemia (cll)
WO2014085802A1 (en) 2012-11-30 2014-06-05 The Broad Institute, Inc. High-throughput dynamic reagent delivery system
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CN105102467B (zh) 2013-02-07 2019-01-22 新泽西鲁特格斯州立大学 高度选择性核酸扩增引物
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
EP3628322A1 (en) 2013-03-01 2020-04-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer
EP2961415B1 (en) 2013-03-01 2021-01-06 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
US10176294B2 (en) 2013-03-15 2019-01-08 The Broad Institute, Inc. Accurate typing of HLA through exome sequencing
BR112015025460B1 (pt) 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
US20160215042A1 (en) 2013-04-19 2016-07-28 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
WO2014184744A1 (en) 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
US9890393B2 (en) 2013-05-29 2018-02-13 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system
EP3293275B1 (en) * 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
KR102429859B1 (ko) 2013-12-06 2022-08-04 더 브로드 인스티튜트, 인코퍼레이티드 신생물 백신을 위한 제형
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
DK3152569T3 (da) 2014-06-05 2020-08-17 Aimm Therapeutics Bv Midler og fremgangsmåder til bestemmelse af t-cellegenkendelse
PT3198026T (pt) 2014-08-07 2020-01-16 Pharmassist Ltd Método de determinação do estado mutacional de pik3ca numa amostra
EP3198031A1 (en) 2014-09-22 2017-08-02 Dana Farber Cancer Institute, Inc. Use of clonal evolution analysis for ibrutinib resistance in chronic lymphocytic leukemia patients
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
WO2016164833A1 (en) * 2015-04-08 2016-10-13 Nantomics, Llc Cancer neoepitopes
WO2016172722A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
WO2016183042A1 (en) 2015-05-10 2016-11-17 Quandx Inc. Ultra sensitive probes for detection of nucleic acid
RU2020132040A (ru) 2015-05-20 2020-10-12 Те Брод Инститьют Инк. Общие неоантигены
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
SG11201808196UA (en) 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide

Also Published As

Publication number Publication date
IL255769A (en) 2018-01-31
JP6913032B2 (ja) 2021-08-04
IL294183B1 (en) 2023-06-01
JP7282834B2 (ja) 2023-05-29
US10835585B2 (en) 2020-11-17
RU2017144467A3 (es) 2019-11-20
JP2023103405A (ja) 2023-07-26
TWI806815B (zh) 2023-07-01
HK1251148A1 (zh) 2019-01-25
MY190974A (en) 2022-05-25
RU2020132040A (ru) 2020-10-12
TW201808327A (zh) 2018-03-16
HK1252267A1 (zh) 2019-05-24
BR112017024797A2 (pt) 2018-08-07
MX2023005122A (es) 2023-07-13
AU2016264623A1 (en) 2017-12-07
RU2733754C2 (ru) 2020-10-06
CN108025048B (zh) 2022-10-25
CR20200476A (es) 2020-12-02
IL302102A (en) 2023-06-01
ECSP17084137A (es) 2018-05-31
WO2016187508A3 (en) 2017-01-12
TW202346325A (zh) 2023-12-01
CN108025048A (zh) 2018-05-11
WO2016187508A2 (en) 2016-11-24
CN116196401A (zh) 2023-06-02
PE20180670A1 (es) 2018-04-19
CO2017012835A2 (es) 2018-05-10
KR20180010229A (ko) 2018-01-30
EP3297660A2 (en) 2018-03-28
JP2018522822A (ja) 2018-08-16
JP2021176866A (ja) 2021-11-11
PH12017502321A1 (en) 2018-06-25
CL2023002421A1 (es) 2024-02-09
CR20170584A (es) 2018-03-20
IL294183B2 (en) 2023-10-01
AU2016264623B2 (en) 2022-06-30
AU2022241521A1 (en) 2022-12-01
CR20230191A (es) 2023-07-06
US20200368337A1 (en) 2020-11-26
CA2986235A1 (en) 2016-11-24
IL294183A (en) 2022-08-01
IL255769B1 (en) 2023-05-01
IL255769B2 (en) 2023-09-01
US20180153975A1 (en) 2018-06-07
RU2017144467A (ru) 2019-06-20
CL2017002945A1 (es) 2018-04-27

Similar Documents

Publication Publication Date Title
MX2023005122A (es) Neoantigenos compartidos.
MX2022005060A (es) Novedosos peptidos y combinaciones de peptidos para usarse en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon no microcitico (nsclc) y otros canceres.
PH12017500484A1 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
EA201792242A1 (ru) Новые пептиды и комбинации пептидов и их каркасы для применения в иммунотерапии колоректальной карциномы (крк) и других видов рака
AU2022205209B2 (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
MX2018005374A (es) Nuevos peptidos y combinacion de peptidos para el uso en la inmunoterapia contra varios tipos de cancer.
MX2018004140A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer pulmonar microcelular y otros tipos de cancer.
EA201791853A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака
EA201891699A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
PH12020500051A1 (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
MY196837A (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
MY190083A (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
MX2020011793A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
PH12018500665A1 (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers